Skip to main content
    C

    Champions Oncology Inc (CSBR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.56
    -0.14 (-3.08%)

    Market Cap: $65.49M

    Last updated: Nov 17, 2026 at 10:50 AM ET

    Champions Oncology Inc (CSBR) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Champions Oncology (CSBR) trades at 1.0x sales and 16.3x book value. Its P/S of 1.0x is below its 5-year median of 1.6x. Its forward P/E is 22.9x.

    Current Multiples

    Its enterprise value is 133.8x its EBITDA.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E22.9x
    Price to sales1.0x
    Price to book16.3x
    EV/EBITDA133.8x
    PEGN/A
    FCF yield-9.7%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 54.5% below 2.2x and its P/B is 28.2% below 22.7x.

    MultipleCurrent5-year median10-year median
    P/S1.0x1.6x2.2x
    P/B16.3x19.1x22.7x
    Medians of month-end values through Oct 2026: 51 to 57 months (5-year) and 108 to 117 months (10-year).

    Valuation History

    Over the 5 of the 10 year ends shown that have a P/E, its P/E ranged from 20.3x in 2025 to 857.0x in 2024. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$6.9120.3x1.6x22.9x
    2024$8.57857.0x2.2x171.1x
    2023$5.62N/A1.5x815.6x
    2022$4.51112.8x1.1x6.7x
    2021$8.36119.4x2.5x13.9x
    2020$10.79N/A3.6x20.5x
    2019$8.33N/A3.4x45.8x
    2018$7.81260.3x3.8x44.2x
    2017$3.88N/A2.4x114.3x
    2016$2.53N/A1.8x8.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CSBR

    What is CSBR's forward P/E ratio?

    Champions Oncology has a forward P/E ratio of 22.9x.

    Is CSBR stock overvalued?

    GNG's valuation label for CSBR is Undervalued.

    What is CSBR's price to sales ratio?

    Champions Oncology has a price to sales ratio of 1.0x.